Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network
Shineco (NASDAQ: SISI) has announced a groundbreaking partnership with Plus Me Limited to launch the world's first blockchain-based cell asset tokenization platform. The initiative includes the creation of "Cell Infusion Redemption Tokens" on the Ethereum mainnet, enabling digital custody and trading of biological cellular assets.
The company has also acquired a 51% controlling stake in Xi'an Dong'ao Health Management Co., Ltd., strengthening its global storage and infusion network. This strategic acquisition, combined with its existing Singapore-based Infiniclone operations, establishes a comprehensive infrastructure for token redemption and asset settlement.
The platform will utilize ERC-1400/ERC-20 compliant security tokens, with smart contracts ensuring asset ownership rights and regulatory compliance through non-fungible digital identifiers (NFDIs). The ecosystem aims to transform traditional biotech marketing while addressing industry challenges such as high costs and illiquid asset pools.
Shineco (NASDAQ: SISI) ha annunciato una partnership innovativa con Plus Me Limited per il lancio della prima piattaforma al mondo di tokenizzazione di asset cellulari basata su blockchain. L'iniziativa prevede la creazione di "Cell Infusion Redemption Tokens" sulla mainnet di Ethereum, permettendo la custodia digitale e la negoziazione di asset cellulari biologici.
La società ha inoltre acquisito una quota di controllo del 51% in Xi'an Dong'ao Health Management Co., Ltd., rafforzando la sua rete globale di stoccaggio e infusione. Questa acquisizione strategica, unita alle operazioni esistenti di Infiniclone con sede a Singapore, costituisce un'infrastruttura completa per il riscatto dei token e la liquidazione degli asset.
La piattaforma impiegherà security token conformi a ERC-1400/ERC-20, con smart contract che garantiranno i diritti di proprietà sugli asset e la conformità normativa tramite identificatori digitali non fungibili (NFDI). L'ecosistema punta a rivoluzionare il marketing biotecnologico tradizionale affrontando problemi del settore come i costi elevati e la scarsa liquidità degli asset.
Shineco (NASDAQ: SISI) ha anunciado una asociación innovadora con Plus Me Limited para lanzar la primera plataforma del mundo de tokenización de activos celulares basada en blockchain. La iniciativa comprende la creación de "Cell Infusion Redemption Tokens" en la mainnet de Ethereum, permitiendo la custodia digital y el comercio de activos celulares biológicos.
La compañía también ha adquirido una participación mayoritaria del 51% en Xi'an Dong'ao Health Management Co., Ltd., reforzando su red global de almacenamiento e infusión. Esta adquisición estratégica, junto con las operaciones existentes de Infiniclone en Singapur, establece una infraestructura integral para el canje de tokens y la liquidación de activos.
La plataforma usará security tokens compatibles con ERC-1400/ERC-20, con contratos inteligentes que aseguran los derechos de propiedad de los activos y el cumplimiento regulatorio mediante identificadores digitales no fungibles (NFDI). El ecosistema busca transformar el marketing biotecnológico tradicional y abordar retos de la industria como los altos costos y la baja liquidez de los activos.
Shineco (NASDAQ: SISI)는 Plus Me Limited와 혁신적 파트너십을 체결하고 세계 최초의 블록체인 기반 세포 자산 토큰화 플랫폼을 출범한다고 발표했습니다. 이 계획에는 이더리움 메인넷에 "Cell Infusion Redemption Tokens"를 발행하여 생물학적 세포 자산의 디지털 보관 및 거래를 가능하게 하는 내용이 포함됩니다.
회사는 또한 Xi'an Dong'ao Health Management Co., Ltd.의 지배지분 51%를 인수하여 글로벌 보관·주입 네트워크를 강화했습니다. 이 전략적 인수는 싱가포르 소재 Infiniclone 운영과 결합되어 토큰 환급 및 자산 정산을 위한 종합 인프라를 구축합니다.
플랫폼은 ERC-1400/ERC-20 호환 보안토큰을 활용하며, 스마트 계약을 통해 자산 소유권과 규제 준수를 비가역 디지털 식별자(NFDI)로 보장합니다. 이 생태계는 높은 비용과 비유동적 자산 풀 등 업계 과제를 해결하면서 전통적인 바이오텍 마케팅을 변화시키는 것을 목표로 합니다.
Shineco (NASDAQ: SISI) a annoncé un partenariat novateur avec Plus Me Limited pour lancer la première plateforme mondiale de tokenisation d'actifs cellulaires basée sur la blockchain. L'initiative prévoit la création de "Cell Infusion Redemption Tokens" sur le réseau principal Ethereum, permettant la conservation numérique et la négociation d'actifs cellulaires biologiques.
La société a également acquis une participation majoritaire de 51% dans Xi'an Dong'ao Health Management Co., Ltd., renforçant ainsi son réseau mondial de stockage et d'infusion. Cette acquisition stratégique, combinée aux opérations existantes d'Infiniclone à Singapour, établit une infrastructure complète pour le rachat des tokens et le règlement des actifs.
La plateforme utilisera des security tokens conformes ERC-1400/ERC-20, des contrats intelligents garantissant les droits de propriété des actifs et la conformité réglementaire via des identifiants numériques non fongibles (NFDI). L'écosystème vise à transformer le marketing biotechnologique traditionnel tout en répondant aux défis du secteur tels que les coûts élevés et les pools d'actifs peu liquides.
Shineco (NASDAQ: SISI) hat eine wegweisende Partnerschaft mit Plus Me Limited angekündigt, um die weltweit erste blockchain-basierte Plattform zur Tokenisierung von Zellvermögenswerten zu starten. Die Initiative umfasst die Schaffung von "Cell Infusion Redemption Tokens" auf dem Ethereum-Mainnet und ermöglicht digitale Verwahrung und den Handel mit biologischen Zellvermögenswerten.
Das Unternehmen hat zudem eine Mehrheitsbeteiligung von 51% an der Xi'an Dong'ao Health Management Co., Ltd. erworben und damit sein globales Lager- und Infusionsnetzwerk gestärkt. Diese strategische Übernahme zusammen mit den bestehenden Infiniclone-Aktivitäten in Singapur schafft eine umfassende Infrastruktur für Token-Einlösung und Asset-Abwicklung.
Die Plattform wird security tokens nach ERC-1400/ERC-20 nutzen, wobei Smart Contracts Eigentumsrechte und regulatorische Konformität über nicht fungible digitale Identifikatoren (NFDIs) sicherstellen. Das Ökosystem zielt darauf ab, traditionelles Biotech-Marketing zu verändern und Branchenprobleme wie hohe Kosten und illiquide Asset-Pools anzugehen.
- First-mover advantage in blockchain-based cell asset tokenization
- Strategic acquisition of 51% stake in Xi'an Dong'ao Health Management strengthens infrastructure
- Creation of liquid, tradable digital instruments from biological assets
- Development of global storage and infusion network through strategic acquisitions
- Implementation of ERC-1400/ERC-20 compliant security tokens enhances regulatory compliance
- Complex integration challenges between blockchain and biological asset management
- Regulatory uncertainty in cross-jurisdictional tokenized biological assets
- Potential technological risks associated with smart contract implementation
Insights
Shineco combines blockchain tokenization with stem cell therapy, creating a novel business model through strategic acquisition and partnerships.
Shineco has pioneered a groundbreaking convergence of blockchain technology with biotech by establishing the world's first on-chain tokenization platform for cellular assets. This represents a fundamental transformation of their business model, transitioning from a traditional biotech service provider to an infrastructure layer for a decentralized cell economy.
The partnership with Plus Me Limited introduces several technical innovations with practical applications. The implementation of non-fungible digital identifiers (NFDIs) on Ethereum's mainnet creates immutable proof of cellular asset ownership and provenance, addressing a critical pain point in the industry where authenticity verification has historically been challenging. The ERC-1400/ERC-20 compliant security tokens introduce a novel liquidity mechanism for previously illiquid biological assets.
The strategic acquisition of a 51% controlling stake in Xi'an Dong'ao Health Management demonstrates execution capability beyond conceptual planning. This acquisition, combined with their previously acquired Singapore firm Infiniclone, establishes a critical global network that bridges the gap between digital tokens and physical cellular assets - solving the 'last mile' problem that has plagued many real-world asset (RWA) tokenization projects.
The business model innovation centers on transforming cellular assets into programmable financial instruments while maintaining biological integrity. The token burning mechanism upon redemption creates engineered scarcity that could potentially drive token value appreciation. The open ecosystem approach, where Shineco provides physical infrastructure while Plus Me delivers the tokenization layer, creates network effects that could scale more rapidly than a closed system.
This initiative reflects broader market trends where RWA tokenization is gaining institutional adoption, though regulatory frameworks remain inconsistent across jurisdictions. The inclusion of governance rights through future DAO voting indicates an evolving business structure that may decentralize certain decision-making processes while maintaining corporate control of critical infrastructure.
Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant mesenchymal stem cells (MSCs) on the Ethereum mainnet. Smart contracts will immutably secure asset ownership rights, issuing unique non-fungible digital identifiers (NFDIs) for each cellular asset to ensure traceability and compliance. Verifiable uniqueness and regulatory compliance are cryptographically enforced through on-chain hashing.
Plus Me will issue ERC-1400/ERC-20 compliant security tokens, branded as "Cell Infusion Redemption Tokens." These utility tokens can be redeemed at Shineco-affiliated Cell Therapy Centers, with Tokens are programmatically burned upon redemption, enforcing scarcity and aligning long-term value for stakeholders. This RWA (Real-World Asset) tokenization framework addresses critical industry pain points: high user costs, unverifiable product provenance, and illiquid asset pools – converting biological assets into tradable digital instruments.
To bolster the initiative, Shineco has secured a controlling
The parties will co-build an open-cell industry ecosystem: Plus Me provides tokenization SaaS to third parties, while Shineco opens its physical custody network. Shineco maintains off-chain biological QA, with Plus Me ensuring on-chain regulatory compliance – creating cross-jurisdictional synergy with entities like
Shineco's asset tokenization protocol aligns with the industry's shift from clinical trials to commercial scalability. "This marks the birth of a decentralized biotech economy—where every cell becomes a liquid, programmable asset, unlocking unprecedented value for medicine and investors alike," said Jennifer Zhan, CEO of Shineco. "Token holders gain governance rights, including future DAO voting to enhance global ecosystem development in cell therapy—fundamentally transforming traditional marketing paradigms."
About Plus Me Limited
Plus Me provides enterprise-grade blockchain middleware, offering end-to-end solutions for digital asset compliance, tokenomics architecture, and cross-border liquidity deployment. The firm architects Web3 economic models with global exchange partnerships.
About Xi'an Dong'ao Health Management Co., Ltd.
Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols.
About Shineco, Inc.
Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information about Shineco, please visit www.biosisi.com/.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For media inquiries or partnership opportunities, contact:
Shineco, Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
View original content:https://www.prnewswire.com/news-releases/shineco-unveils-worlds-first-on-chain-cell-asset-tokenization-platform-strategic-acquisition-expands-global-blockchain-biotech-network-302534286.html
SOURCE Shineco,Inc.
FAQ
What is Shineco's new blockchain-based cell asset tokenization platform?
What company did Shineco (SISI) acquire in August 2025?
How will Shineco's Cell Infusion Redemption Tokens work?
What is the significance of Shineco's tokenization platform for the biotech industry?
How does Shineco ensure regulatory compliance in its tokenization platform?
